310 related articles for article (PubMed ID: 17093363)
1. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting.
Ho KY; Gan TJ
Curr Opin Anaesthesiol; 2006 Dec; 19(6):606-11. PubMed ID: 17093363
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting.
Janicki PK
Med Sci Monit; 2005 Oct; 11(10):RA322-8. PubMed ID: 16192915
[TBL] [Abstract][Full Text] [Related]
3. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
4. Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype.
Janicki PK; Schuler HG; Jarzembowski TM; Rossi M
Anesth Analg; 2006 Apr; 102(4):1127-33. PubMed ID: 16551910
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis of postoperative nausea and vomiting: controversies in the use of serotonin 5-hydroxytryptamine subtype 3 receptor antagonists.
Kovac AL
J Clin Anesth; 2006 Jun; 18(4):304-18. PubMed ID: 16797435
[TBL] [Abstract][Full Text] [Related]
6. 5-HT3 receptor antagonists for prevention of late acute-onset emesis.
Constenla M
Ann Pharmacother; 2004 Oct; 38(10):1683-91. PubMed ID: 15316106
[TBL] [Abstract][Full Text] [Related]
7. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
8. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis.
Neufeld SM; Newburn-Cook CV
J Neurosurg Anesthesiol; 2007 Jan; 19(1):10-7. PubMed ID: 17198095
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative vomiting following craniotomy: two studies in children and young adults.
Neufeld SM; Newburn-Cook CV
Can J Neurosci Nurs; 2009; 31(1):30-4. PubMed ID: 19397073
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting: the role of pharmacogenetics.
Theodosopoulou P; Rekatsina M; Staikou C
Minerva Anestesiol; 2023 Jun; 89(6):565-576. PubMed ID: 36852569
[TBL] [Abstract][Full Text] [Related]
12. The role of neurokinin-1 receptor antagonists for the management of postoperative nausea and vomiting.
Apfel CC; Malhotra A; Leslie JB
Curr Opin Anaesthesiol; 2008 Aug; 21(4):427-32. PubMed ID: 18660647
[TBL] [Abstract][Full Text] [Related]
13. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
de Wit R; Aapro M; Blower PR
Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
[TBL] [Abstract][Full Text] [Related]
14. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
Rojas C; Stathis M; Thomas AG; Massuda EB; Alt J; Zhang J; Rubenstein E; Sebastiani S; Cantoreggi S; Snyder SH; Slusher B
Anesth Analg; 2008 Aug; 107(2):469-78. PubMed ID: 18633025
[TBL] [Abstract][Full Text] [Related]
15. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?
Gan TJ
CNS Drugs; 2005; 19(3):225-38. PubMed ID: 15740177
[TBL] [Abstract][Full Text] [Related]
16. Granisetron: an update on its clinical use in the management of nausea and vomiting.
Aapro M
Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of Postoperative Nausea and Vomiting.
Aroke EN; Hicks TL
J Perianesth Nurs; 2019 Dec; 34(6):1088-1105. PubMed ID: 31227296
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of the use of rescue antiemetics following PONV prophylactic failure with 5-HT3 antagonist/dexamethasone versus single-agent therapies.
Kovac AL
Ann Pharmacother; 2006 May; 40(5):873-87. PubMed ID: 16670361
[TBL] [Abstract][Full Text] [Related]
19. Management of postdischarge nausea and vomiting after ambulatory surgery.
Melton MS; Klein SM; Gan TJ
Curr Opin Anaesthesiol; 2011 Dec; 24(6):612-9. PubMed ID: 21934496
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms in the cytochrome P450 system and efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting.
Nielsen M; Olsen NV
Br J Anaesth; 2008 Oct; 101(4):441-5. PubMed ID: 18782884
[No Abstract] [Full Text] [Related]
[Next] [New Search]
